AstraZeneca said on Aug. 26 a late-stage trial showed the company’s medicine for a rare disease that causes accumulation of copper in the body was three times more successful in helping remove deposits from tissues compared with standard care.

At an outer suburban manufacturing plant, engineer Byron Kennedy is resetting a machine to spray-print a layer of copper on to a door handle, aiming to use the metal’s antiviral properties to counter the threat of the COVID-19 pandemic.